Verséa Holdings is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases. Verséa operates distinct divisions including pharmaceuticals, diagnostics, medical education, and consumer wellness, each providing value to the healthcare community and driving commercial success.
Management & Medical Advisors
The Verséa team has 350+ years of pharmaceutical and diagnostic regulatory, developmental and commercialization expertise with proven success in highly regulated markets. The collective experience of the team spans commercial and clinical operations build-outs, serving at US drug regulatory agencies, achieving FDA product approvals, successful product launches, private practice physicians and lifecycle management. Recently, Verséa has become a single source for the top EUA by FDA COVID-19 diagnostic testing and screening options for healthcare providers. Versea was awarded IRB Approval for the first HIPPA Compliant Patient Registry in the USA around a specific product line (Verséa Product).
Products & Services target the healthcare provider as a primary distribution channel to the patient. Practitioners receive scientific information, medical education, training and ongoing support on products and services from Verséa in addition to incremental practice revenue Verséa products generate. The combination of education and revenue generating offerings differentiates and drives loyalty with Verséa!
The Verséa R&D team includes 25+ leading physicians and researchers each regarded as the top in their specialty. Ongoing discovery and R&D is viewed as the cornerstone for long-term growth of the company and primary differentiator from others in our market segment. In this regard, Verséa is committed to the medical hemp R&D program through self-funding, pursuit of grant funding from agencies including the National Institute of Health (NIH) and more importantly the publication of our data. The Diagnostics division has formed partnerships granting access to EUA granted by FDA COVID-19 testing with high global demand. Our advisors are involved in the conduct of ongoing multi-site studies throughout the country in private practices.
The foundation of our pharmaceutical division is a novel drug discovery platform with the ability to efficiently screen thousands of compounds annually saving millions in failed studies and trials, this platform creates a scientific data set for all pipeline assets emerging from the platform. The Verséa medical hemp products currently utilize proprietary technology, processes, and materials to promote bioavailability and absorption levels. Our diagnostics division supplies PCR extended respiratory panel (ERP), Serology, Antigen-COVID 19 test kits and drug screening kits. All tests have been FDA approved or granted Emergency Use Authorization (EUA) by the FDA. Our practice solutions division is preparing for the launch of a robust chronic care and disease management platform allowing practitioners to monetize specific patients in their practice through the delivery of automated care regimens.